Aurobindo Pharma's board approved a ₹800 crore share buyback on April 6, 2026, via tender offer route at ₹1,475 per share—a premium of about 10-11.6% over recent closing prices around ₹1,335. The company will repurchase up to 54,23,728 equity shares (0.93% of total paid-up capital), with April 17, 2026 as the record date to determine eligible shareholders.

This move signals strong cash confidence amid robust US generics demand and healthy free reserves.

Aurbindo Pharma Approves Rs. 800 Cr Buyback Key Details :-

The buyback excludes transaction costs like brokerage and taxes.

Process Timeline (Expected)

1. Record Date: April 17, 2026 – Hold shares by this date to participate.
2. Tender Opens: Likely ~April 20-25 (post-record, SEBI norms).
3. Tender Closes: ~5-7 days after opening.
4. Settlement: Within T+2 of closure.
5. Extinguishment: Shares cancelled post-buyback.

Shareholders tender via broker/CDS; acceptance proportionate to holdings.

Why Aurobindo approved Buyback ?

Capital Allocation: Returns excess cash to shareholders amid ₹800 Cr outlay (small vs. reserves).indiaipo+1
EPS Boost: Reduces outstanding shares, lifting earnings per share.
Valuation Signal: Management sees stock undervalued at current levels.
Business Backdrop: Strong USFDA approvals, API growth, debt reduction.

Stock Market Impact

Buyback news typically supports price stability and premium realisation for tendering shareholders. Aurobindo traded around ₹1,335 pre-announcement; post-buyback floor near ₹1,475 possible if market aligns.

Strengths

• 10-11.6% premium for eligible shareholders.
• Proportionate acceptance for all holders.
• Strong cash position (3.93% of standalone reserves).
• EPS accretion post-buyback.
• Signals management confidence in growth.

Risks

• Proportionate acceptance may limit full tender.
• Market price could exceed buyback price.
• Execution delays or lower acceptance.
• Ongoing USFDA scrutiny in pharma.
• Currency/volatility impacts forex earnings.

FAQs

Q1: What is the buyback size and price?
₹800 Cr at ₹1,475/share (54.24L shares).upstox+1

Q2: When is the record date?
April 17, 2026.+2

Q3: Who can participate?
All shareholders (promoters incl.) on proportionate basis.kotakneo+1

Q4: How to tender shares?
Via your broker/depository post-tender opening.

Q5: What % of capital?
0.93% of total equity shares.upstox+1

Q6: Impact on EPS/stock price?
Likely EPS boost; supports valuation.

Q7: Any costs excluded?
Yes, brokerage/taxes not in ₹800 Cr size.